Phio Pharmaceuticals Corp.
PHIONASDAQHealthcare● Active
$1.09
+$0.03(+2.83%)
Market Cap$12662803
P/E Ratio—
52W High$4.19
52W Low$0.813
Phio Pharmaceuticals Corp. (PHIO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PHIO · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.34
Est. -$0.24 · -41.7%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS
PHIO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.36 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.24 | -$0.34 | -41.7% | — | — | — |
| ▲ Q1 FY2026 | Mar 5, 2026 | -$0.34 | -$0.15 | +55.9% | — | — | — |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.45 | -$0.44 | +2.2% | — | — | — |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.36 | -$0.45 | -25.0% | — | — | — |
| — Q2 FY2025 | May 15, 2025 | — | -$0.41 | — | — | — | — |
| ▲ Q1 FY2025 | Mar 31, 2025 | -$1.23 | -$0.85 | +30.9% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$4.14 | -$1.54 | +62.8% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.36
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$0.34
EPS Est.
-$0.24
EPS Surpr.
-41.7%
Revenue
—
Q1 FY2026
Mar 5, 2026Beat
EPS Actual
-$0.15
EPS Est.
-$0.34
EPS Surpr.
+55.9%
Revenue
—
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.44
EPS Est.
-$0.45
EPS Surpr.
+2.2%
Revenue
—
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$0.45
EPS Est.
-$0.36
EPS Surpr.
-25.0%
Revenue
—
Q2 FY2025
May 15, 2025
EPS Actual
-$0.41
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 31, 2025Beat
EPS Actual
-$0.85
EPS Est.
-$1.23
EPS Surpr.
+30.9%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$1.54
EPS Est.
-$4.14
EPS Surpr.
+62.8%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.25 | $-0.25 | $-0.25 | 1 |
| Q3 FY2027 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Q2 FY2027 | $-0.22 | $-0.22 | $-0.22 | 1 |
| Q1 FY2027 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q4 FY2026 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Q3 FY2026 | $-0.33 | $-0.33 | $-0.31 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -41.7% | $1.15 | $1.14 | -0.87% |
| ▲ Q1 FY2026 | Mar 5, 2026 | +55.9% | $1.15 | $1.17 | +1.74% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +2.2% | $1.58 | $1.43 | -9.49% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -25.0% | $2.19 | $2.19 | +0.00% |
| — Q2 FY2025 | May 15, 2025 | — | $1.86 | $1.78 | -4.30% |
| ▲ Q1 FY2025 | Mar 31, 2025 | +30.9% | $1.29 | $1.30 | +0.78% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +62.8% | $2.35 | $2.23 | -5.11% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +21.1% | $2.62 | $2.62 | +0.00% |
Q2 FY2026-0.87%
Report Date
May 7, 2026
EPS Beat/Miss
-41.7%
Price Before
$1.15
Price After
$1.14
Q1 FY2026+1.74%
Report Date
Mar 5, 2026
EPS Beat/Miss
+55.9%
Price Before
$1.15
Price After
$1.17
Q4 FY2025-9.49%
Report Date
Nov 13, 2025
EPS Beat/Miss
+2.2%
Price Before
$1.58
Price After
$1.43
Q3 FY2025+0.00%
Report Date
Aug 14, 2025
EPS Beat/Miss
-25.0%
Price Before
$2.19
Price After
$2.19
Q2 FY2025-4.30%
Report Date
May 15, 2025
EPS Beat/Miss
—
Price Before
$1.86
Price After
$1.78
Q1 FY2025+0.78%
Report Date
Mar 31, 2025
EPS Beat/Miss
+30.9%
Price Before
$1.29
Price After
$1.30
Q4 FY2024-5.11%
Report Date
Nov 14, 2024
EPS Beat/Miss
+62.8%
Price Before
$2.35
Price After
$2.23
Q3 FY2024+0.00%
Report Date
Aug 14, 2024
EPS Beat/Miss
+21.1%
Price Before
$2.62
Price After
$2.62
Avg Beat Reaction-2.42%
Avg Miss Reaction-0.43%
Beat Rate5 / 8 quarters
Largest Move-9.49% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PHIO ends December
Phio Pharmaceuticals Corp. (PHIO) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.34 — missing the analyst consensus of $-0.24 by -41.7%. The next PHIO earnings date is expected around September 1, 2026.
Each quarter, investors track PHIO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PHIO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PHIO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PHIO earnings · 5 questionsPhio Pharmaceuticals Corp.'s next earnings report is expected around September 1, 2026. PHIO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PHIO historically reports after market close (AMC).
PHIO earnings datewhen is PHIO earningsPHIO next earnings datewhen does PHIO report earningsPHIO earnings calendar
▸ Source: FMP · Phio Pharmaceuticals Corp. SEC filings · US GAAP · Phio Pharmaceuticals Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026